secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2024-07-02T23:59:59+00:00
Accession:  0001437749-24-021877
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic enters recombinant albumin partnership with Proliant; $1.5M upfront milestone payments + profit share
--------------------------------------------------------------------------------

- Dyadic receives $1.5M upfront milestone payment and profit share from Proliant for recombinant albumin license.
- First product (recombinant human serum albumin) expected to launch in first half of 2025.
- Partnership targets ~$6B serum albumin market for cell culture, vaccine, medical device, diagnostic segments.
- Dyadic's COO states agreement demonstrates strategy to commercialize products and generate near-term revenue in Alternative Proteins.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000143774924021877/0001437749-24-021877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000143774924021877/dyai20240627_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-021877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer